27 July 2026
InMode expands women’s wellness portfolio with acquisition of Viveve patents
InMode has further cemented its position as a leader in women’s wellness, purchasing the intellectual property assets of Vieve Medical Inc.
Vieve offers safe and effective medical treatment for vaginal laxity and female urinary incontinence.
The acquisition of the Viveve patents will expand InMode’s offerings in women’s wellness, which already includes Empower RF, a comprehensive non-surgical platform delivering life-changing women’s treatments, through bipolar radiofrequency (RF) and electrical muscle stimulation (EMS) to treat a broad range of conditions including, urinary incontinence, weak pelvic floor muscles, blood circulation, and pain relief.
“Development of products for women’s wellness continues to be a strategic pillar of our long-term growth strategy,” said Moshe Mizray, InMode CEO.
“By investing in new patents and licensing rights, InMode is not only strengthening its intellectual property portfolio but is also reaffirming its commitment to commercialising innovative technologies”.
InMode Australia Managing Director, Dennis Cronje said InMode is proud to be expanding in a market where there is increasing demand.
“Women are increasingly becoming aware they don’t need to suffer in silence with problems relating to vaginal laxity and the acquisition of Vieve patents means InMode will be able to offer even more solutions”.
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for aesthetic medicine, gynecology, dermatology and ophthalmology.
0408 445 694